

1 **XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2**
2 **accelerates the recovery of mild to moderate COVID-19 patients and keeps**
3 **its neutralizing activity against Omicron and its subvariants.**

4

5 Garyfallia Poulakou¹, Pierre-Joseph Royer², Nikolai Evgeniev³, Gwénaëlle Evanno²,
6 Françoise Shneiker², Bernard Vanhove², Odile Duvaux², Stéphane Marot⁴ Vincent Calvez⁴.

7

8 ¹3rd Department of Internal Medicine, Medical School, Sotiria General Hospital, National and
9 Kapodistrian University of Athens, 11527 Athens, Greece.

10 ²Xenothera, Nantes, France.

11 ³Complex Oncology Center, Department of Medical oncology, Russe, Bulgaria.

12 ⁴Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé
13 Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière
14 Hospital, Department of Virology, Paris, France.

15

16

17 **ABSTRACT**

18 **Background:** XAV-19 is a glyco-humanized swine polyclonal antibody targeting
19 SARS-CoV-2. The safety and clinical efficacy of XAV-19 was investigated in patients with a
20 WHO score of 2 to 4 in the WHO 7-point ordinal scale. The activity of XAV-19 against
21 Omicron and its subvariants was assessed *in vitro*.

22 **Methods:** A phase II/III, multicentric randomized double-blind placebo-controlled,
23 clinical trial was conducted to evaluate the safety and clinical efficacy of XAV-19 in
24 inpatients with COVID-19 requiring or not oxygen therapy and outpatients not requiring
25 oxygen (EUROXAV trial, NCT04928430). Most patients were not vaccinated. The primary
26 endpoint was the proportion of patients with an aggravation of COVID-19 within 8 days after
27 treatment. Binding and neutralization of Omicron or its subvariants by XAV-19 was
28 investigated by ELISA or with a whole virus neutralization assay.

29 **Results:** Patients received either 150mg of XAV-19 (N=139) or placebo (N=140).
30 Low enrolment forced the premature trial termination. XAV-19 was well tolerated. No
31 difference in the primary endpoint, nor in the proportion with an improvement at day 8
32 (secondary endpoint) was observed between the 2 groups. For patients not requiring oxygen
33 therapy, XAV-19 reduced the time to improvement significantly (7 days vs 14 days
34 p=0.0159). Neutralizing activity against Omicron and BA.2, BA.2.12.1, BA.4/5 and BQ1.1
35 subvariants was shown *in vitro*.

36 **Conclusions:** XAV-19 did not reduce the aggravation in COVID-19 patients. While it
37 did not bring any benefit to patients requiring oxygen, it reduced the time to improvement for
38 patients not requiring oxygen (WHO score 2 or 3). These preliminary clinical data might
39 indicate a therapeutic potential for patients with mild to moderate COVID-19 requiring
40 supplementation with anti-SARS-CoV-2 neutralizing antibodies.

41 **Key word:** SARS-COV-2, (Glyco-Humanized) polyclonal antibody, XAV-19, Omicron.

42 **INTRODUCTION**

43 Since the beginning of the Coronavirus disease 2019 (COVID-19) pandemic, caused
44 by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), mass vaccination
45 campaigns from December 2020, dramatically reduced the impact of SARS-CoV2, limiting
46 the pandemic and reducing the number of deaths. Yet, prophylactic or therapeutic drugs are
47 still needed for immunocompromised patients or people who do not respond to the
48 vaccination (1,2).

49 Numerous neutralizing monoclonal antibodies (mAb) have been developed against
50 SARS-CoV-2. Most of them were raised against the original Wuhan-type virus and see their
51 neutralization potential abrogated or reduced against variants. Moreover, mAb may favor the
52 emergence of SARS-CoV-2 resistant variant in immunocompromised patients (3). Also,
53 approved anti-SARS-CoV-2 mAb are no more recommended since end 2022 since they are
54 unlikely to be effective against emerging strains of SARS-CoV-2 (4–6). Owing to their
55 potential to bind multiple target epitopes and maintain their neutralizing activity despite
56 mutations, polyclonal antibodies (pAbs) from animal origin represent a promising approach
57 against COVID-19 (7,8). Hyperimmunization of qualified and selected animals guarantees
58 large volumes of high-titer and controlled pAb. Moreover, the whole process of production
59 and purification is quick, affordable and compatible with clinical manufacturing. Thereby,
60 pAbs against SARS-CoV-2 are being tested in clinical trials (9–11).

61 We developed XAV-19, a swine glyco-humanized polyclonal antibody (GH-pAb)
62 directed against the Wuhan-type SARS-CoV-2 RBD (12). XAV-19 is produced in alpha 1,3-
63 galactosyltransferase (GGTA1)/cytidine monophosphate-N-acetylneuraminic acid
64 hydroxylase (CMAH) double KO pigs, preventing the formation of immune complexes thus
65 avoiding post-infusion serum sickness and allergies (13). Clonal origin of the double KO pigs

66 limits the risk for batch-to-batch variation. XAV-19 broadly neutralizes variants (14) and has
67 been introduced in clinic since 2020 where it displayed no major safety issues in a phase IIa
68 clinical trial for patients under oxygen (9). Considering the later publications on the benefits
69 of anti-SARS-CoV-2 antibodies when administered early, we investigated the clinical impact
70 of XAV-19 for patients (in- or out-) suffering from mild to moderate COVID19. The results
71 of the EUROXAV study (NCT04928430, EudraCT: 2020-005979-12), an international,
72 placebo-controlled, double-blind, randomized clinical trial designed to evaluate the efficacy
73 and safety of XAV-19 in patients with moderate COVID-19 requiring or not oxygen therapy
74 are presented. Besides, as SARS-CoV-2 keep evolving, the activity of XAV-19 against
75 Omicron and its current spreading subvariants was tested.

76

77 **METHODS**

78 **Phase II/III Trial**

79 **Study design.** EUROXAV (NCT04928430; EudraCT: 2020-005979-12) was a multicenter,
80 international phase II/III, double-blind, placebo-controlled, randomized clinical trial
81 conducted in 14 hospitals from 5 countries (Bulgaria, Greece, Romania, Spain, Turkey)
82 between March 2021 and October 2022. This trial followed the International Council for
83 Harmonization E6 guideline for good clinical practice and the principles of the Declaration of
84 Helsinki. An independent data safety monitoring board (DSMB) examined the data for safety
85 on a regular basis during the trial.

86

87 **Participants.** Adult patients must have SARS-CoV-2-confirmed infection (RT-PCR, RT-
88 qPCR or antigen test in the last 10 days) and present signs of respiratory disease with at least
89 2 clinical symptoms related to COVID-19 started less than 10 days prior to screening visit.
90 Patients should have SpO₂ > 90% (at ambient air) and require or not low-flow oxygen
91 therapy (score 2, 3 or 4 on WHO clinical progression 7-point ordinal scale (15)). Exclusion
92 criteria were a positive SARS-CoV-2 test > 10 days, multiorgan failure, immediate ICU
93 hospitalization, critical respiratory illness, requirement of oxygenation at flow rate > 6L/min,
94 or signs of severe systemic illness (respiratory rate \geq 30 per min, heart rate \geq 125 per min,
95 PaO₂/FiO₂ < 300), participation of another trial, pregnancy or breastfeeding. Eligible patients
96 were randomized in a 1:1 ratio to receive either XAV-19 (150mg) diluted in sterile NaCl
97 0.9% or placebo (NaCl 0.9% only) as a 1-hour intravenous perfusion. Randomization was
98 stratified by center and by WHO score (WHO score = 2 or 3 versus WHO score = 4). Patients
99 were monitored during the infusion and the following hour. On the investigator judgement,
100 the patient was either hospitalized or discharged (ambulatory patients). Dexamethasone,
101 antithrombotic prophylaxis, antibiotics and antiviral medication (except anti-SARS-CoV-2

102 mAb or convalescent plasma) were allowed according to the judgement of the investigator
103 and to the national guidelines or standard of care.

104

105 **Sample size calculation.** Sample size calculation initially assumed 15% progression of
106 COVID-19 in the placebo arm versus 8% in the XAV-19 arm and a two-sided 5% type I error
107 rate. A sample of 650 patients would provide the trial with 80% power. Considering a drop-
108 out rate of 25%, 870 patients were planned.

109

110 **Primary endpoint.** The primary endpoint was the proportion of patients with an aggravation
111 of COVID-19 within 8 days. The aggravation was defined as a worsening of the score of at
112 least 1 point on the WHO 7-point ordinal scale compared to the score at randomization.

113

114 **Secondary endpoints.** Secondary endpoints were proportion of patients with an aggravation
115 of COVID-19 within 8 days after treatment (defined as a worsening of the score of at least 2
116 points on the WHO clinical progression 7-point ordinal scale compared to the score at
117 randomization); proportion of patients with an aggravation/improvement of COVID-19
118 between day 8 and day 15 (defined as a worsening/improvement of the score of at least 1
119 point on the WHO 7-point ordinal scale); time to aggravation/improvement measured by the
120 proportion of patients with an aggravation/improvement at each measurement days (3, 5, 8,
121 15) after randomization. Safety outcomes included the cumulative incidence of any Adverse
122 Event (AE). A stratified log rank-test will be used to compare treatment effect between
123 groups, after adjustment on the stratification variables at baseline.

124

125 **Statistical analyses.** The global alpha type I error with bilateral hypotheses for this study was
126 fixed at 5%. Binary logistic regression model was performed for the primary efficacy

127 analysis. Association between the randomization group and the progression of COVID-19
128 was adjusted on centre, WHO score, country, age, body mass index (BMI), gender and
129 comorbidities (defined as BMI>30, diabetes DNID, diabetes DID, cardiac disorder, vascular
130 disorder, hypercholesterolemia, renal failure, lung disease COPD and/or asthma). For efficacy
131 analyses, the strategy “Missing=Failure” is performed for patients who withdraw before D8 or
132 for patients with missing data. Under this strategy, patients without an available assessment at
133 D8 will be considered as having an aggravation. Replacement of missing data is done in the
134 ITT and TARGET populations. The comparisons between XAV-19 group and placebo group
135 of two or more qualitative variables was made using the χ^2 test, the continuity-corrected χ^2
136 test or Fisher exact test, according to the expected values under the assumption of
137 independence. Comparisons of quantitative variables between XAV-19 and placebo groups
138 were made using a Student t-test (parametric test comparing means) or Mann-Whitney-
139 Wilcoxon test (non-parametric test comparing ranks) depending on the distribution of the
140 variable of interest. A log rank test was used to compare time to aggravation/improvement
141 between randomization groups. Kaplan-Meier curves are presented by randomization groups
142 and by WHO score at baseline.

143

144 **Spike/ACE-2 neutralization assay.** Recombinant SARS-CoV-2 RBD (1 μ g/ml in
145 carbonate/bicarbonate buffer pH 9.0) were immobilized overnight at 4°C on Maxisorp
146 microtiter plates. After washes and saturation with PBS-Tween 0.05%-BSA2%, successive
147 dilutions of XAV-19 or tixagevimab/cilgavimab were added for 30 min, followed by ACE-2-
148 mFc Tag ligand (Sino Biological; final concentration 125 ng/ml). After 1h incubation and
149 washing, the ACE-2 mFc Tag was revealed using a peroxidase-conjugated anti-mouse
150 secondary antibody. Binding intensity was revealed by addition of TMB. Reaction was
151 stopped with 50 μ l of 1M H₂S₀₄ and optical density was taken at 450 nm.

152 **Cytopathogenic Effect (CPE).** Vero cells (CCL-81) and Vero E6 cells (CRL-1586) were
153 obtained from ATCC. SARS-CoV-2 clinical isolates were isolated from SARS-CoV-2 RT-
154 PCR positive patients and viral stocks were generated by one passage on Vero cells. Titration
155 of viral stock was performed on Vero E6 by limiting dilution assay allowing calculation of
156 tissue culture infective dose 50% (TCID₅₀). Serial dilutions of XAV-19 (50µl) were
157 incubated with 50µl of virus (2 x 10³ TCID₅₀/ml) in a 96-well plate at 37°C for 60min in 8
158 replicates. Hundred µl of Vero E6 cell (3 x 10⁵ cells/ml) were then added to the mixture and
159 incubated at 37°C, 5% CO₂ until microscopy examination on day 4 to assess CPE. For viral
160 load (VL) quantification, RNA extraction of the 8 pooled replicates of each XAV-19 dilution
161 was performed with NucliSENS EasyMag (BioMerieux) according to manufacturer's
162 protocol. The relative VL were assessed from cycle threshold values for ORF1ab gene
163 obtained by the TaqPath™ COVID-19 RT-PCR (ThermoFisher, Waltham, USA) and by
164 linear regression in log₁₀ copies/ml with a standard curve realized from a SARS-CoV-2
165 positive nasopharyngeal sample quantified by Droplet-Digital PCR (Bio-Rad).

166

167

168

169 **RESULTS**

170 **Phase II/III**

171 **Demographic and patient characteristics.** EUROXAV was initiated in 2021 and expected
172 to enrol 870 patients. Yet, due to the very low enrolment rate, the study was unlikely to be
173 completed in a reasonable timeline and was suspended on October 31, 2022. An interim blind
174 analysis was performed in November 2022, and the results were shared with the Independent
175 DSMB who recommended to stop the study. At that time, 293 patients with confirmed
176 COVID-19 were screened. Eligible patients were randomized to receive XAV-19 (N=139) or
177 placebo (N=140) (Figure 1). Final analyses were performed on target population defined as
178 ITT patients having received at least one dose of treatment and fulfilling the main inclusion
179 criteria, *i.e.* aged 18 or over, weighing between 40 and 120kg at the time of signing the
180 informed consent, requiring or not low-flow oxygen therapy ($\leq 6\text{L}/\text{min}$) with WHO score at 2,
181 3 or 4, (129 and 130 patients in the XAV-19 and the placebo arms respectively). The
182 demographic and clinical characteristic at baseline were similar between groups. The median
183 age was 56.4 years and 54.5% were male patients. Percentage of patients with a WHO score
184 of 2, 3 and 4 was 25.6, 45.7 and 28.7 in the XAV-19 arm and 25.4, 46.2, 28.5 in the placebo
185 arm (Table 1). While comorbidities were slightly higher in the XAV-19 arm (62% in XAV-19
186 group vs 49 in placebo group), both groups were comparable for age, gender, BMI, and WHO
187 score.

188

189 **Primary efficacy endpoint.** The primary endpoint was the proportion of patients with an
190 aggravation of COVID-19 within 8 days after treatment. No differences on aggravation
191 according to the treatment group was observed (12 vs 9 patients in the XAV19 and the
192 placebo arm respectively, OR: 1.379, 95% CI 0.560 to 3.394, $p=0.4831$) (Table 2). Bivariate

193 analyses showed that age at screening or comorbidities were associated with COVID-19
194 progression, while gender, BMI, or WHO score were not (Table 2). Logistic regression
195 confirmed the association between age (over 70) and aggravation of COVID-19 ($p=0.001$, OR
196 = 6.675 [2.158; 20.645]) (not shown).

197

198 **Secondary endpoints.** There was no difference in the proportion of patients with COVID-19
199 aggravation within 8 days of treatment in the XAV-19 arm *vs* the placebo arm. Proportion of
200 patients with COVID aggravation at day 15 was similar between groups. Proportion of
201 patients with COVID-19 aggravation/improvement at day 15 *vs* day 8 was also similar
202 between XAV-19 and placebo arms (not shown). Although proportions of
203 aggravation/improvement were not different between groups, improvement did occur earlier
204 in the XAV-19 arm ($p=0.0340$) (Figure 2A). This benefit was even more significant for non-
205 hospitalized patients (WHO score of 2 at day 1) or patients not requiring supplemental oxygen
206 (WHO score of 2 or 3 at day 1) ($p=0.0003$ and $p=0.0159$) while not significant for
207 hospitalized patients (WHO score of 3 or 4) or hospitalized patients requiring supplemental
208 oxygen (WHO score of 4) ($p=0.7511$ and $p=0.8059$). Furthermore, median time to
209 improvement was reduced in the XAV-19 arm compared to the placebo one (4 days *vs* 14
210 days and 7 days *vs* 14 days for patients with a WHO score at baseline of 2 and 2/3
211 respectively) (Figure 2B). By contrast, time to aggravation was not different between XAV-
212 19 and placebo groups (not shown).

213

214 **Safety.** A total of 83 adverse event (AE) (45 in the XAV-19 arm and 38 in the placebo arm)
215 were observed from 29 patients in each group (Table 3). The percentage of mild/moderate AE
216 in the XAV-19 arm was 91% (*vs* 76.3% in the placebo arm). Twenty-two severe AE (SAE)
217 were reported in the XAV-19 group compared to 13 in the placebo group. None of them were

218 considered as related by the investigators. Interestingly, SAE >3 account for 86% of SAE in
219 the XAV-19 arm vs 92% in the placebo arms. Number of fatal SAE was equivalent between
220 the two groups with 5 deaths in each group, from respiratory failure, multi-organ failure or
221 disease progression. No anaphylaxis or hypersensitivity reactions and no infusion-related
222 events were reported in any patients receiving XAV-19.

223

224 To further explore XAV-19 clinical potential, the neutralizing activity of XAV-19 against
225 Omicron and its subvariants was determined.

226

227 **In vitro antiviral activity**

228 **XAV-19 antiviral efficacy against Omicron and its subvariants.** Binding of XAV-19 to
229 Omicron, BA.2, BA2.12.1, BA.4/5 and BQ1.1 RBD appeared slightly lower than binding to
230 the original strain RBD. Yet, similar plateau was reached whatever the variant tested (Figure
231 3A, top). In comparison, binding of the association tixagevimab/cilgavimab (Evusheld®) to
232 Omicron or BA.4/5 RBD was dramatically reduced, and binding to BQ1.1 RBD was
233 completely abolished. Although binding of BA2 and BA2.12.1 subvariants was less affected,
234 a lower plateau was obtained (Figure 3A, bottom).

235 XAV-19 neutralization potential was then tested in an RBD/ACE-2 binding
236 competition assay. Comparable dose response profiles with full neutralization by XAV-19
237 were obtained with all the variants tested (Figure 3B, left); IC₅₀ was moderately increased
238 (5.9 ± 0.2 and $9.1 \pm 0.6 \mu\text{g/mL}$ for Wuhan and Omicron RBD respectively). By contrast,
239 neutralization efficacy of tixagevimab/cilgavimab was limited to 60% for Omicron versus
240 100% for Wuhan RBD (Figure 3B, right). XAV-19 neutralization of viral infectivity was
241 confirmed by CPE assay using SARS-CoV-2 clinical isolates. XAV-19 neutralized 100% of
242 CPE for all the variants tested and reached 100% viral load reduction (Figure 3C) with

243 slightly varying NT50 concentrations. Interestingly, NT50 against Omicron was in the low
244 range in CPE and lower than for all other variants in VL assessment.

245 **XAV-19 targets epitopes outside the Omicron mutations.** Four main target epitopes
246 of XAV-19 (347-fasvyawnr-417, 409-qiapgqtgn-417, 445-vsgnylylrlfrksnlkpferdisteiy-473
247 and 530-stnlvk-535) were identified on Omicron RBD by proteolytic epitope mapping (Figure
248 4, bold), including 6 amino acids out of the 17 (in blue) directly involved in ACE-2 receptor
249 binding. Among the 15 Omicron mutations in RBD (in yellow), only 2 lie inside the major
250 XAV-19 target epitopes (N417 and S446) compared to 5 for the association
251 tixagevimab/cilgavimab (underlined; K440, S446, N477, K478, A484)(16).

252

253 .

254 **DISCUSSION**

255 Although vaccination is now the primary option against SARS-CoV-2, therapeutic
256 drugs are still needed for immunocompromised or at-risk individuals. The potential of anti-
257 SARS-COV-2 mAb is today largely dampened by the continual emergence of resistant
258 variants (4,5,17) and as SARS-CoV-2 will probably continue to mutate, robust and variant
259 resistant treatments are still necessary.

260 The therapeutic potential of XAV-19 was investigated in the phase II/III EUROXAV
261 study. Treatment with XAV-19 was safe and well tolerated. The fact that no patient who
262 received XAV-19 had anaphylaxis or hypersensitivity reactions, confirms the validity of our
263 glyco-humanization strategy. Yet, our trial suffered from a low inclusion rate and was stopped
264 after inclusion of 293 patients. In addition, the proportion of worsening cases within the
265 placebo arm was far lower than initially expected (8% observed vs 15% expected). This
266 reduction in disease severity, although most patients were not vaccinated, might be due to the
267 improvement in the management of COVID-19 patient (18,19) and/or to the infection of
268 patients with the Omicron strain, known to be less pathogenic than the original one (20).
269 Therefore, the low frequency of events, and the reduced recruitment rate, lowered
270 dramatically the power of the study and the primary endpoint was not met. Nevertheless, we
271 showed that XAV-19 efficiently modulated the kinetic of COVID-19 disease as it accelerated
272 the clinical improvement of patients not requiring high-flow oxygen therapy (WHO score \leq
273 4). More precisely, XAV-19 benefits to patients not requiring oxygen, while it does not bring
274 any benefit to oxygen-dependent patients (WHO score 4). In that respect, our data match
275 recent studies showing the suitability of therapeutics antibodies in patients with mild to
276 moderate COVID-19 (21–23).

277

278 We have previously shown the neutralization efficiency of XAV-19, against the
279 original Wuhan and the Alpha, Beta, Gamma and Delta variants (8). Here the neutralization
280 activity of XAV-19 against Omicron and its subvariants was confirmed, while the association
281 tixagevimab/cilgavimab (Evusheld®) lost its activity, as already published (17). Interestingly,
282 XAV-19 even neutralized BQ1.1 subvariant, against which most mAb or cocktails of mAb are
283 devoid of activity (17,24). Neutralization potency of XAV-19 was also confirmed on live
284 Omicron by CPE assay. As the correlation between neutralization ELISA and CPE assay had
285 been previously shown, (8), our data strongly suggest the ability of XAV-19 to neutralize live
286 Omicron subvariants.

287 Due to its high number of mutations (30 mutations in the spike protein, 15 in the
288 RBD), Omicron showed resistance to more than 80% of the therapeutic antibody candidate
289 (25). Yet these mutations represent only 3% of the main target epitopes of XAV-19. The
290 transmissibility of SARS-CoV-2 results from a fine balance between affinity to ACE-2 and
291 capacity to escape immune response. The need to maintain sufficient affinity to ACE-2
292 probably limits SARS-CoV-2 RBD mutability as shown by the R493Q reversion mutation
293 observed on the Omicron variants (26). Whereas antibody avidity allows to overcome SARS-
294 CoV-2 variability (25), our data confirm that targeting multiple alternative epitopes, grants
295 pAb to keep their binding and neutralization capacity (8). Thereby, the neutralizing activity of
296 XAV-19, was confirmed so far on the 5 main SARS-CoV-2 variants that have emerged since
297 the beginning of the pandemic.

298 Limitations of the study are the following. The 7-point ordinal scale WHO score as
299 main endpoint, may suffer from discrepancies among practices in the different countries /
300 hospitals; and standardized criteria for use of oxygen or hospitalization have not been
301 implemented in this trial. Another limitation is the absence of information about vaccination

302 though most patients were not vaccinated due to the main enrolment period from Jan to Sept
303 2021 (268 patients included) in locations where the vaccines were not available yet.

304

305 Altogether our data support XAV19 as a potent and affordable therapeutic option in
306 patients with mild to moderate COVID-19, that could complement mAb antibody strategies.
307 Today, absence of robust, variant resistant anti-SARS-COV-2 mAb therapy for
308 immunocompromised individuals remains a public health concern (27). XAV-19 could be
309 specially proposed for those high-risk patients.

310

311 **Funding:** This project has received funding from Bpifrance and from the European Union's
312 Horizon 2020 research and innovation programme under grant agreement



313 No 962036. **bpi**france | **SERVICES CAPEBIRD**

314

315

316 **Acknowledgments:** We wish to thank all the patients, family members and staff from all the
317 units that participated in the study.

318

319 **EUROXAV study group:** Todor Atanasov, Dan Corneci, Valentin Cuervas-Mons, Gheorghe
320 Lulian Diaconescu, Nikolay Evgeniev, Gerd Fätkenheuer, Elizabeth George, Rosen Georgiev,
321 Benoit Guery, Guillen Santiago Moreno, Bedreag Ovidiu-Horea, Diamantis Kofteridis, Ali
322 Mert, Symeon Metallidis, Hristo Metev, Cristina Mussini, Garyfallia Poulakou, Emmanuel
323 Roilides, Fehmi Tabak, Pilar Vizcarra.

324

325 **Potential conflicts of interest.** PJR, GE, FS, BV and OD are employees of Xenothera.

326

327

328 References

- 329 1. DeWolf S, Laracy JC, Perales M-A, Kamboj M, van den Brink
330 MRM, Vardhana S. SARS-CoV-2 in immunocompromised
331 individuals. *Immunity* (2022) 55:1779–1798. doi:
332 10.1016/j.immuni.2022.09.006
- 333 2. Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD,
334 Ho A, Aston S, Wootton DG, Richter A, et al. Outcome of COVID-
335 19 in hospitalised immunocompromised patients: An analysis of
336 the WHO ISARIC CCP-UK prospective cohort study. *PLoS Med*
337 (2023) 20:e1004086. doi: 10.1371/journal.pmed.1004086
- 338 3. Gupta A, Konnova A, Smet M, Berkell M, Savoldi A, Morra M, Van
339 averbeke V, De Winter FHR, Peserico D, Danese E, et al. Host
340 immunological responses facilitate development of SARS-CoV-2
341 mutations in patients receiving monoclonal antibody treatments.
342 *Journal of Clinical Investigation* (2023) 133:1–13. doi:
343 10.1172/JCI166032
- 344 4. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G,
345 Tuccori M. Monoclonal antibody therapies against SARS-CoV-2.
346 *Lancet Infect Dis* (2022) 22:e311–e326. doi: 10.1016/S1473-
347 3099(22)00311-5
- 348 5. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A.
349 Analysis of immune escape variants from antibody-based
350 therapeutics against covid-19: A systematic review. *Int J Mol Sci*
351 (2022) 23: doi: 10.3390/ijms23010029
- 352 6. Widyasari K, Kim J. A Review of the Currently Available Antibody
353 Therapy for the Treatment of Coronavirus Disease 2019 (COVID-
354 19). *Antibodies* (2023) 12:5. doi: 10.3390/antib12010005
- 355 7. Cunha LER, Stolet AA, Strauch MA, Pereira VAR, Dumard CH,
356 Gomes AMO, Monteiro FL, Higa LM, Souza PNC, Fonseca JG, et al.
357 Polyclonal F(ab')₂ fragments of equine antibodies raised against
358 the spike protein neutralize SARS-CoV-2 variants with high
359 potency. *iScience* (2021) 24: doi: 10.1016/j.isci.2021.103315
- 360 8. Vanhove B, Marot S, So RT, Gaborit B, Evanno G, Malet I,
361 Lafrogne G, Mevel E, Ciron C, Royer P-J, et al. XAV-19, a Swine
362 Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike
363 Receptor-Binding Domain, Targets Multiple Epitopes and Broadly
364 Neutralizes Variants. *Front Immunol* (2021) 12:1–11. doi:
365 10.3389/fimmu.2021.761250
- 366 9. Gaborit B, Dailly E, Vanhove B, Josien R, Lacombe K, Dubee V,
367 Ferre V, Brouard S, Ader F, Vibet M, et al. Pharmacokinetics and
368 Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-
369 CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a

- 370 Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
371 *Antimicrob Agents Chemother* (2021) 65:1–13. doi:
372 10.1128/AAC.01237-21
- 373 10. Lopardo G, Belloso WH, Nannini E, Colonna M, Sanguineti S,
374 Zylberman V, Muñoz L, Dobarro M, Lebersztein G, Farina J, et al.
375 RBD-specific polyclonal F(ab')₂ fragments of equine antibodies in
376 patients with moderate to severe COVID-19 disease: A
377 randomized, multicenter, double-blind, placebo-controlled,
378 adaptive phase 2/3 clinical trial. *EClinicalMedicine* (2021)
379 34:100843. doi: 10.1016/j.eclinm.2021.100843
- 380 11. Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger
381 AL, Bausch C, Luke T, Hoover K, et al. Phase 2 safety and antiviral
382 activity of SAB-185, a novel polyclonal antibody therapy for non-
383 hospitalized adults with COVID-19. *J Infect Dis* (2023)1–6. doi:
384 10.1093/infdis/jiad013
- 385 12. Vanhove B, Duvaux O, Rousse J, Royer PJ, Evanno G, Ciron C,
386 Lheriteau E, Vacher L, Gervois N, Oger R, et al. High neutralizing
387 potency of swine glyco-humanized polyclonal antibodies against
388 SARS-CoV-2. *Eur J Immunol* (2021) 51:1412–1422. doi:
389 10.1002/eji.202049072
- 390 13. Dhar C, Sasmal A, Varki A. From “Serum Sickness” to
391 “Xenosialitis”: Past, Present, and Future Significance of the Non-
392 human Sialic Acid Neu5Gc. *Front Immunol* (2019) 10:807. doi:
393 10.3389/fimmu.2019.00807
- 394 14. Vanhove B, Marot S, So RT, Gaborit B, Evanno G, Malet I,
395 Lafrogne G, Mevel E, Ciron C, Royer P-J, et al. XAV-19, a Swine
396 Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike
397 Receptor-Binding Domain, Targets Multiple Epitopes and Broadly
398 Neutralizes Variants. *Front Immunol* (2021) 12:1–11. doi:
399 10.3389/fimmu.2021.761250
- 400 15. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai
401 Y, Wei M, et al. A Trial of Lopinavir–Ritonavir in Adults
402 Hospitalized with Severe Covid-19. *New England Journal of*
403 *Medicine* (2020) 382:1787–1799. doi: 10.1056/nejmoa2001282
- 404 16. Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen
405 RE, Case JB, Sutton RE, Gilchuk P, et al. Genetic and structural
406 basis for SARS-CoV-2 variant neutralization by a two-antibody
407 cocktail. *Nat Microbiol* (2021) 6:1233–1244. doi:
408 10.1038/s41564-021-00972-2
- 409 17. Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck H-M, Pöhlmann S,
410 Hoffmann M. Omicron sublineage BQ.1.1 resistance to
411 monoclonal antibodies. *Lancet Infect Dis* (2023) 23:22–23. doi:
412 10.1016/S1473-3099(22)00733-2

- 413
414
415
416
417
18. Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, Ke FY, Su SC, Liang KH, Yuan JPY, et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. *J Biomed Sci* (2022) 29:1–36. doi: 10.1186/s12929-022-00852-9
- 418
419
420
421
422
423
19. Brady DK, Gurijala AR, Huang L, Hussain AA, Lingan AL, Pembroke OG, Ratangee BA, Sealy TT, Vallone KT, Clements TP. A guide to <scp>COVID</scp> -19 antiviral therapeutics: a summary and perspective of the antiviral weapons against <scp>SARS-CoV</scp> -2 infection. *FEBS J* (2022)1–31. doi: 10.1111/febs.16662
- 424
425
426
427
428
429
20. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL, Kall M, Bhatt S, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet* (2022) 399:1303–1312. doi: 10.1016/S0140-6736(22)00462-7
- 430
431
432
433
434
21. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, Sarkis E, Solis J, Zheng H, Scott N, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19. *JAMA* (2022) 327:1236. doi: 10.1001/jama.2022.2832
- 435
436
437
438
439
22. Huang DT, McCreary EK, Bariola JR, Minnier TE, Wadas RJ, Shovel JA, Albin D, Marroquin OC, Kip KE, Collins K, et al. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge. *JAMA Netw Open* (2022) 5:e2220957. doi: 10.1001/jamanetworkopen.2022.20957
- 440
441
442
443
444
445
23. O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas R V., Barouch DH, et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. *JAMA* (2022) 327:432–441. doi: 10.1001/jama.2021.24939
- 446
447
448
449
450
24. Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, Grzelak L, Prot M, Mougari S, Planchais C, et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. *Nat Commun* (2023) 14:824. doi: 10.1038/s41467-023-36561-6
- 451
452
453
454
455
25. Callaway HM, Hastie KM, Schendel SL, Li H, Yu X, Shek J, Buck T, Hui S, Bedinger D, Troup C, et al. Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. *Cell Rep* (2023) 42:112014. doi: 10.1016/j.celrep.2023.112014

- 456
457
458
459
460
461
462
463
464
465
466
26. Huo J, Dijokaite-Guraliuc A, Liu C, Zhou D, Ginn HM, Das R, Supasa P, Selvaraj M, Nutalai R, Tuekprakhon A, et al. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. *Cell Rep* (2023) 42:111903. doi: 10.1016/j.celrep.2022.111903
 27. Casadevall A, Focosi D. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. *Journal of Clinical Investigation* (2023) 133:1–3. doi: 10.1172/JCI168603

467 **FIGURE LEGENDS**

468 **Figure 1. Clinical Trial Design.**

469

470 **Table 1. Demographic and baseline characteristics by treatment groups.**

471

472 **Table 2. Bivariate analysis between categorical variables and aggravation of COVID-19.**

473

474 **Figure 2. Time to clinical improvement.** Kaplan-Meier curves by randomization group on
475 whole TARGET population (**A**) or on TARGET population with a score of 2, 2 to 3, 3 to 4 or
476 4 at baseline (**B**). Improvement was defined as a diminution of at least 1 point on the WHO
477 score compared to the WHO score at day 1. Dotted lines represent the median time to
478 improvement.

479

480 **Table 3. Adverse and serious adverse events.**

481

482 **Figure 3: XAV-19 antiviral activity against Omicron and its subvariants.** Binding of
483 XAV-19 or Evusheld to Wuhan or Omicron and its subvariant RBD (**A**). XAV-19 or
484 Evusheld were added to RBD coated plates at the indicated concentration and revealed with
485 an HRP-conjugated secondary anti-pig or anti-human antibody. Neutralizing activity of XAV-
486 19 or Evusheld to Wuhan or Omicron and its subvariant RBD (**B**). Recombinant His-Tag-
487 RBD pre-incubated with XAV-19 or Evusheld were added to human ACE2 coated plates.
488 Bound RBD were then detected with HRP-conjugated anti-His-Tag antibody. Neutralizing
489 activity of XAV-19 on whole replicating viruses (**C**). Vero E6 cells were infected with Wuhan

490 or Omicron SARS-CoV-2 strains. CPE was assessed by microscopy examination and viral
491 load percentage was determined by quantitative RT-PCR.

492

493 **Figure 4: XAV-19 target epitopes lie outside the Omicron mutation sites.** Amino acid
494 sequence of the SARS-CoV-2 spike RBD variant Omicron and XAV-19 target epitopes
495 (amino acid sequence numbered according to DBSOURCE sequence reference
496 NC_045512.2). Bold: XAV-19 target epitopes confirmed by proteolytic epitope mapping;
497 blue: amino acids in contact with ACE-2; yellow: mutations found in Omicron, differentiating
498 from the original Wuhan RBD, underlined: Tixagevimab/Cilgavimab target epitopes.

499

500

501

502

503

504

505




Figure 1: Flow chart of the clinical trial

Characteristic	XAV-19 (N=129)	PLACEBO (N=130)	Total (N=259)
Age at screening, mean (SD)	57.5 (15.0)	55.2 (15.4)	56.4 (15.2)
Nb of male patients, n (%)	74 (57.4)	67 (51.5)	141 (54.4)
BMI, mean (SD)	28.3 (4.7)	28.2 (4.6)	28.2 (4.7)
Current smoker, n (%)	14 (11.0)	16 (12.5)	30 (11.8)
WHO score at day 1, n (%)			
WHO 2	33 (25.6)	33 (25.4)	66 (25.5)
WHO 3	59 (45.7)	60 (46.2)	119 (45.9)
WHO 4	37 (28.7)	37 (28.5)	74 (28.6)
Comorbidities[§], n (%)	80 (62.0)	64 (49.2)	144 (55.6)
Immunocompromised patients, n (%)	11 (8.5)	11 (8.5)	22 (8.5)
Time between first COVID-19 symptoms and treatment in days, mean (SD)	2.3 (2.3)	2.6 (2.5)	2.5 (2.4)
Vital signs			
Systolic blood pressure, mmHg, mean (SD)	125.1 (14.6)	124.8 (16.3)	124.9 (15.5)
Diastolic blood pressure, mmHg, mean (SD)	76.5 (9.4)	75.9 (9.8)	76.2 (9.6)
Body temperature, mean (SD)	37.3 (0.7)	37.2 (0.8)	37.3 (0.7)
Respiratory examination			
Signs of pneumonia [¥] , n (%)	122 (94.6)	120 (93.0)	242 (93.8)
Onset of the oldest COVID-19 symptom in days, mean (SD)	5.5 (2.4)	5.6 (2.6)	5.5 (2.5)
SpO2 at ambient air (%), mean (SD)	94.9 (1.8)	94.7 (2.1)	94.8 (1.9)
Patients under O2 supplementation, n (%)	37 (28.7)	37 (28.5)	74 (28.6)

¥: determined by chest X ray, CT scan or auscultation

§: BMI>30, diabetes DNID, diabetes DID, cardiac disorder, vascular disorder, hypercholesterolemia, renal failure, lung disease COPD and/or asthma

Table 1: Demographics and baseline characteristics by treatment group.

Parameters	No Worsening N=238	Worsening N= 21	Total N=259	<i>P-values</i>	<i>OR</i> [95/% IC]
Treatment, n (%)					
XAV19	117 (90.7)	12 (9.3)	129		
PLACEBO	121 (93.1)	9 (6.9)	130	<i>0.4831</i>	1.379 [0.560; 3.394]
Age at screening, n (%)					
≤ 50 years	87 (97.8)	2 (2.2)	89		
> 50 years	151 (88.8)	19 (11.2)	170	<i>0.0124</i>	5.473 [1.245; 24.061]
≤ 60 years	144 (96)	6 (4)	150		
> 60 years	94 (86.2)	15 (13.8)	109	<i>0.0045</i>	3.829 [1.435; 10.221]
≤ 70 years	196 (95.6)	9 (4.4)	205		
> 70 years	42 (77.8)	12 (22.2)	54	<i>0.0001</i>	6.222 [2.464; 15.712]
≤ 80 years	230 (92.7)	18 (7.3)	248		
> 80 years	8 (72.7)	3 (27.3)	11	<i>0.0498</i>	4.792 [1.169; 19.645]
Gender, n (%)					
Male	130 (92.2)	11 (7.8)	141		
Female	108 (91.5)	10 (8.5)	118	<i>0.8433</i>	0.914 [0.374; 2.233]
BMI, mean (SD)	28.2 (4.8)	27.8 (2.6)	28.2		
Weight range n (%)					
Malnutrition : < 18.5	0	0	0		
Normal weight: [18.5;25[65 (97)	2 (3)	67		
Overweight: [25;30[92 (88.5)	12 (11.5)	104		
Moderate obesity: [30;35[61 (92.4)	5 (7.6)	66		
Severe obesity: [35;40[15 (6.3)	0 (0)	15		
Morbid or massive obesity: ≥ 40	5 (2.1)	1 (5.0)	6	<i>0.1561</i>	NA
WHO score at day 1, n (%)					
WHO 2/3	170 (91.9)	15 (8.1)	185		
WHO 4	68 (91.9)	6 (8.1)	74	<i>1</i>	1.000 [0.372; 2.685]
Comorbidities, n (%)					
NO	111 (96.5)	4 (3.5)	115		
YES	127 (88.2)	17 (11.8)	144	<i>0.0147</i>	3.715 [1.214; 11.368]

Table 2: Bivariate analysis between categorical variables and aggravation of COVID-19.







A**B**

Figure 2 : Time to clinical improvement


	XAV-19 (N=139)		Placebo (N=140)	
	Number of patients	Number (%) of AE/SAE	Number of patients	Number (%) of AE/SAE
Any adverse event, N (%)	29	45 (54.2)	29	38 (45.8)
Mild/moderate AE, N (%/number of AE)		41 (91.1)		29 (76.3)
Related to XAV-19 or placebo, N (%/number of AE)	8	9 (20.0)	5	5 (13.2)
Any SAE, N (%)	10	22 (62.9)	9	13 (37.2)
SAE>3 N (%/number of SAE)	9	19 (86.3)	8	12 (92.3)
SAE related	0	0	0	0
Infusion-related events	0	0	0	0
Death	5		5	
Cause of death				
Respiratory failure	3		4	
Disease progression	0		1	
Multiorgan failure	1		0	
Cytokine storm	1		0	

Table 3 : Adverse events and serious adverse events

A



B



C




Figure 3: XAV-19 antiviral activity against Omicron and its subvariants

319-rvqptesivrfpnitnlcpfddevfnatr**fasvyawnr**krisncva
 364-dysvlynlapfftfkcygvsptklndlcftnvyadsfvirgdevr**qiapgqgtgn**iadynyk
 425-lpddftgcviawnsnkldskv**sgnynlyrlfrksnlkpferdisteiy**
 474-qag**nk**pcngv**agf**ncy**fplrsysfrptyg**vg**h**qpyrvvvlsfellha
 521-patvcgpk**stnlvk**nkcvnf-541

- X** : XAV-19 epitopes
- X** : AA involved in ACE2 binding
- X** : Omicron mutations
- X : Tixagevimab/Cilgavimab epitopes

Figure 4: XAV-19 target epitopes lying outside the Omicron mutation sites